FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
This article was originally published in The Tan Sheet
Executive Summary
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmareRegister for our free email digests: